FDA approves Axsome Therapeutics' Auvelity for Alzheimer’s agitation
read at Endpoints ↗ApprovalPositive
The U.S. Food and Drug Administration has granted approval to Axsome Therapeutics’ oral medication Auvelity for the treatment of agitation in patients with Alzheimer’s disease.
Axsome noted that agitation affects up to 76 % of individuals with Alzheimer’s, manifesting as pacing, restlessness, and verbal or physical aggression, and the approval provides a new therapeutic option for this unmet need.
In separate news, Esperion Therapeutics announced it will be taken private in a transaction valued at approximately $1.1 billion.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “FDA approval for Alzheimer's agitation drug; Esperion goes private in $1.1B deal”
read at Endpoints ↗77 words · retrieved May 1
comments(0)
5-min edit window · permanent after that